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Background
The HVTN 503/Phambili study, a phase IIB study of the
Merck Ad-5 multiclade HIV vaccine, suspended enroll-
ment and vaccinations following the results of the
HVTN502/STEP study. Participants were notified of their
treatment allocation and continue to be followed. We
investigate the impact of study unblinding on HIV risk
perception and behaviour.
Methods
Before suspension, 801 participants were enrolled. Data
from all participants who had a post-treatment notifica-
tion behaviour risk assessment (PTN-RA) were compared
with the baseline RA. In addition an unblinding risk per-
ception questionnaire was administered post-treatment
notification (PTN).
Results
469 participants were eligible for risk behaviour analysis:
median time between unblinding and administration of
PTN-RA being 70 days (IQR: 39–108 days). At baseline,
amongst men, there were no statistical differences in risk
behaviour reported by treatment arm, and borderline dif-
ferences in unprotected anal sex with a female partner
(0% vaccinee vs. 2.9% placebo arm, p = 0.056), and a STI
diagnosis (7.7% vaccinee vs. 2.2% placebo, p = 0.052).
For women, there were no differences in risk behaviour by
treatment arm at baseline. Post-treatment notification,
risk behaviour change was similar for both sexes, with the
pattern of change being similar in both arms. Between
screening and the PTN-RA, significant reductions in
number of sexual partners (p < 0.001), and unprotected
sex (p < 0.001). were observed. 677 participants com-
pleted the unblinding risk perception questionnaire. In
this assessment, men were more likely to report behaviour
change (22.0%) than women (14.1%). Men reported
increased condom use (64.6%), encouraging partner test-
ing (51.2%) and reduced partner numbers (57.3%). More
vaccinees (24.7%) as compared to placebo recipients
(12.1%) agreed/strongly agreed that they were more likely
to get HIV than most people (p < 0.001), which was attrib-
uted by the participant to receiving the vaccine.
Conclusion
Post-unblinding, vaccinees perceived being at increased
risk of HIV, but risk behaviour reductions were noted irre-
spective of treatment allocation.
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